US Prescription Brand
Net Pricing Data
and Analysis
SSR Health’s US prescription brand pricing data tool incorporates quarterly gross and estimated net pricing data and trends since 2007– and for every quarter going forward.
The dataset includes gross and net prices for the majority of active US brand name prescription drugs – approximately 1,000 products across more than 100 companies.
Our client-focused Tableau Online platform provides standardized analyses of net pricing trends by industry, company, and therapeutic area, and enables clients to perform analyses customized to their specific requirements.
Among the available data series are WAC-to-net concessions, Medicaid versus non-Medicaid concessions, product roll-up to industry, therapeutic area and company levels, and both WAC and net prices by year or course of therapy, enabling in-depth comparisons across products and segments.
Drawing on our proprietary dataset and the expertise of our principals, SSR Health provides analysis on drug pricing trends across the industry, together with political and regulatory developments that are impacting – and are projected to impact – products, segments and companies in the space. Among the areas we focus on:
Quarterly pricing trends.
• SSR Health publishes quarterly reports that identify and assess the positive and negative drivers – by company, therapeutic area and product – of aggregate net pricing trends, as well as the factors influencing pharma market dynamics (e.g., co-pay accumulators, formulary exclusions).
US political and regulatory developments.
• We provide objective and actionable analyses of new and proposed legislation and directives (e.g., The Prescription Drug Pricing Reduction Act (PDPRA), International Pricing Index, Anti-Kickback Statute (AKS) safe harbor rule) and their industry impact.
